<DOC>
	<DOCNO>NCT02519439</DOCNO>
	<brief_summary>A follow-on , two-year open-label extension study ganaxolone add-on therapy adult patient drug-resistant partial-onset seizure</brief_summary>
	<brief_title>A Two-year Open-label Extension Study Ganaxolone Patients With Drug-resistant Partial-onset Seizures</brief_title>
	<detailed_description>This study 2-year , open-label continuation patient benefit ganaxolone treatment complete Protocol 1042-0603 .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Pregnanolone</mesh_term>
	<criteria>Subjects complete scheduled clinical study visit previous protocol 10420603 show minimum 35 % improvement mean 28day seizure frequency last three 28day period study 1042603 compare baseline study 1042603 . Subjects whose daily study drug compliance Study 10420603 90 % great , investigator feel subject compliant full dose prescribe . Able give inform consent writing , legally authorize representative able , properly inform nature risk study prior engage studyrelated procedure . Currently treat maintain stable regimen 1 , 2 , 3 antiepileptic drug ( AED ) consistent dose one month prior study entry . Implanted Vagus Nerve Stimulator ( VNS ) permit count towards number concomitant AEDs . Able willing maintain accurate complete daily write seizure calendar caregiver able willing maintain accurate complete daily write seizure calendar . Able willing take drug food twice daily . Ganaxolone must administer food . Sexually active woman childbearing potential ( WCBP ) must use medically acceptable method birth control negative pregnancy test Visit 1 subsequent visit . Have medical condition , investigator 's judgment , consider clinically significant could potentially affect subject safety study outcome Experienced Serious Adverse Event moderate severe medically important adverse event judge probably definitely related openlabel ganaxolone previous study , 10420603 Have Alanine transferase ( ALT ; SGPT ) Aspartate transferase ( AST ; SGOT ) level &gt; 3 time upper limit normal ( ULN ) , total bilirubin &gt; 1.5 time ULN Study 10420603 . Have history malignancy within past 2 year , exception basal cell carcinoma . Seizures secondary illicit drug alcohol use , infection , neoplasm , demyelinate disease , degenerative neurological disease , central nervous system ( CNS ) disease deem progressive , metabolic illness , progressive degenerative disease . Have active suicidal plan/intent , active suicidal thought past 6 month . Have history actual suicide attempt last 5 year 1 lifetime actual suicide attempt classify ColumbiaSuicide Severity Rating Scale ( CSSRS ) . Have history drug alcohol abuse within past 5 year . As AEDs , use alcohol advise . Are currently follow plan follow ketogenic diet . Current use vigabatrin ezogabine ( retigabine ; Potiga ; Trobalt ) permit . Females pregnant , currently breastfeed plan become pregnant study . Inability/unwillingness withhold grapefruit grapefruit juice diet entire clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Partial Onset Seizures</keyword>
	<keyword>complex partial seizure</keyword>
	<keyword>simple partial seizure</keyword>
	<keyword>anticonvulsant</keyword>
	<keyword>ganaxolone</keyword>
	<keyword>neurosteroid</keyword>
	<keyword>Marinus</keyword>
	<keyword>epilepsy</keyword>
</DOC>